Effectiveness of single dose conivaptan for correction of hyponatraemia in post-operative XXXX following major head and neck surgeries.

@entity1 @entity1372 @entity1951 @entity15707
BACKGROUND AND AIMS: Conivaptan, a @entity1951 receptor antagonist, is commonly used for the treatment of euvolaemic, hypervolaemic hyponatraemia. Usually, an intravenous (IV) bolus followed by infusion is administered for many days. We decided to assess the effectiveness of single dose conivaptan for correction of hyponatraemia in post-operative @entity1 . METHODS: This was a prospective, randomised trial conducted in 40 symptomatic post-operative Intensive Care Unit (ICU) @entity1 with a serum @entity1372 level of  <=130 mEq/L. Group A @entity1 received IV @entity15707 20 mg over 30 min, whereas in group B infusion of 3% hypertonic saline was started as an infusion at the rate of 20-30 ml/h. Serum @entity1372 levels were measured at 12, 24, 48 and 72 h and the daily fluid balance was measured for 3 days. The Chi-square test, Wilcoxon signed rank test and Mann-Whitney tests were used as applicable. RESULTS: The serum @entity1372 levels before initiating treatment were comparable between groups. However, subsequent @entity1372 levels at 12, 24 and 48 h showed significantly high values in group A. Though at 72 h the mean @entity1372 value was high in group A, it was not statistically significant. Group A showed a significantly high fluid loss on day 1, 2 and 3. The mean volume of hypertonic saline required in group B showed a steady decline from day 1 to 3 and only 13 @entity1 required hypertonic saline on the 3(rd) day. CONCLUSION: Single dose conivaptan is effective in increasing serum @entity1372 levels in post-operative ICU @entity1 up to 72 h associated with a significant negative fluid balance.
